Ligand Targretin Symptom Trial Could Support Use For Early CTCL

A trial focusing on symptom improvement of cutaneous T-cell lymphoma patients could demonstrate the utility of Ligand's Targretin for patients with early stage CTCL, FDA's Oncologic Drugs Advisory Committee said Dec. 13.